Investing.com -- Celldex Therapeutics' experimental bispecific antibody CDX-622 demonstrated deep and sustained suppression of serum tryptase, a key marker of ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE